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Abstract
Purpose: The aim of this work was to assess and to quantify, for clinical practice,the differences in computed doses using two types of dose calculation algorithm forthe heterogeneity correction including target volumes and organs at risk (OARs).
Methods: 35 patients having lung, breast, spine, head & neck, brain and pelvictumors, were studied. For each patient, 2 treatment plans were generated. In plan1, the dose was calculated using the Modified Batho's (MB) density correctionmethod integrated in the Pencil Beam Convolution algorithm. In plan 2, the dosewas calculated using the Anisotropic Analytical Algorithm (AAA). To compare thetwo plans a dosimetric analysis was carried out including cumulative anddifferential dose volume histograms (DVH), coverage index, and conformity index.Wilcoxon signed rank and Spearman’s tests were used to calculate p-values andcorrelation coefficients (r), respectively. Bootstrap simulation with 1000 randomsamplings was used to calculate the 95% confidence interval (95% CI). Results:The analysis of DVH showed that the AAA method calculated significantly higherdoses for OARs for all cancer sites and lower doses for target volumes, especiallyfor targets located in lung, with p < 0.05. The data demonstrated a strongcorrelation between MB and AAA for all cancer sites with r > 0.9. Conclusion: Thisstudy confirms that using the AAA integrated into Eclipse® TPS, the calculated dosewill be increased to OARs, and reduced to target volumes. Thus, when changingfrom the MB algorithm to AAA, attention should be paid to avoid any bias ofover/under estimating the dose given by AAA and to hold discussions betweenphysicists and oncologists regarding any necessary modification in the prescriptionmethod.
Keywords: Heterogeneity correction; Modified Batho's density correction; AAA; Medical decision.
1. IntroductionRecent advances in radiotherapy have introducedseveral new dose calculation algorithms to accuratelycompute the prescribed dose according to the variabledensity of heterogeneous tissues.The former algorithms used a correction factor to takeaccount of the heterogeneity of tissues, e.g. densitycorrection methods are integrated into the Pencil BeamConvolution algorithm (PBC) in the Eclipse® TreatmentPlanning System (TPS) (Varian Medical Systems, PaloAlto, CA), such as the Modified Batho's (MB) densitycorrection method. In these algorithms, the alteration in
the lateral transport of electrons is not modelled.1-5Presently, numerous algorithms approximate thetransport of electrons, such as the Anisotropic AnalyticalAlgorithm (AAA) and Collapsed Cone Convolution (CCC)implemented, respectively, in the Eclipse® and Pinnacle®TPS (Philips Radiation Oncology Systems, Fitchburg,WI). More recently, Acuros XB (Varian Medical Systems,Inc., Palo Alto, CA) solves the linear Boltzmann transportequation. In contrast to AAA, the Acuros XB algorithmcalculates dose to a medium, which can be convertedinto the dose to water for treatment plan evaluation.Several studies have demonstrated that AAA and Acuros
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XB algorithms were more accurate for the calculation ofdose within heterogeneous media.[6-9] However, we havelittle knowledge about the impact of heterogeneitycorrections on target volume and organs at risk usingthe AAA algorithms in clinical practice. Recently,numerous studies, recommended that a sufficientnumber of cases for each anatomical site should be usedto evaluate the dose difference resulting from the formerand the new algorithms9. In the present study, we assessand evaluate what the impact would be, when switchingfrom MB to AAA, on doses for six cancer sites exhibitinglower or higher tissue densities.
2. Methods and Materials
2.1 Clinical cases and treatment planningThis study is based on 35 patients and includes sixdifferent cancer types. These cases were chosen to coverthe full range of tumors treated in radiation oncology,namely: lung, breast, spine, head & neck, brain andpelvis. A computed tomography (CT-scan) was carriedout for each patient. Then the images were loaded intothe TPS. The virtual simulation for each patient wasgenerated by a digitally reconstructed radiograph andbeam's eye view information. The planning targetvolumes (PTVs) including the security margins, and theorgans at risk (OARs) were delineated by the radiationoncologist. Table 1 shows the tumor locations, thenumber of PTVs, the prescribed dose and the treatmentfields for all cases.For each patient, two treatment plans were generated.In plan 1, the dose was calculated using the MB methodin combination with the PBC algorithm; this was takenas the reference dose. In plan 2, the dose was calculatedusing AAA. The reference treatment plans were designed
according to the clinical experience of the specialistdepartment and ICRU recommendations. Thesereference plans were validated by a medical physicistregarding two criteria: i) that 95% of the prescribeddose encompassed the PTV and the maximum dosewithin the PTV was under 107% of the prescribed dose;ii) for OARs, that the recommended dose constraintswere respected. Table 2 shows the dose constraintsconsidered for the OARs in all cancer cases. The choiceof plan 1 as the reference plan is based on currentclinical results which have been obtained over manyyears of clinical experience.
2.2 Treatment plan evaluations
2.2.1 Dosimetric analysis
Dose Volume Histogram (DVH): for each PTV, theminimum dose (Dmin), mean dose (Dmean), maximumdose (Dmax) and the calculated dose to 95% of thetarget volume (D95%) were compared using cumulativecDVH. The dose constraints for each OAR, presented inTable 2 were compared.
Quality indices: the Coverage Index (CI) andConformity Index for the target volume (CITV) proposedby the Radiation Therapy Oncology Group (RTOG) werecompared using the following equations10,11:CI = (1)Where Imin is the minimal isodose in gray surroundingthe target and RI is the reference isodose in gray.CITV = % (2)where TV is the target volume.
Table 1: Tumor locations, the PTV, the prescribed dose and the treatment fields for all patients.Cancer sites PTV ccaverage ± σ Prescribed dose [Gy]average [min-max] Techniques Energy[MV] Total fieldsLung( n = 6) 394 ± 194 58.8 [50.8 - 66] 3DRT 18 34Breast( n = 6) 1059 ±248 47.2 [40 - 50.6] 3DRT 6 and 18 38Spine( n = 6) 465.4 ± 221.6 10 [8 - 20] 3DRT 6 and 18 19Head & neck( n = 6) 228.2 ± 135.9 56.9 [44.0 - 69.9] IMRT 6 34Brain(n = 5) 318.2 ± 339.1 57 [54 - 66] IMRT 6 25Pelvis(n = 6) 276.7 ± 249.3 65.3 [52.7 - 76] IMRT 6 42
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Table 2: Dose constraints for OARs in all cancer cases.Cancer sites OARs Dose constraintsLung Lung (minus the PTV) V20 Gy < 30%V30 Gy < 20%Spinal cord + 2 mm Dmax < 45 GyHeart V40 Gy < 30%Breast Lung V20 Gy < 30%V30 Gy < 20%Heart V40 Gy < 30%Spine Spinal cord Dmax < 45 GyKidney Dmean < 18 GyHead & neck Spinal cord Dmax < 45 GyParotid Dmean < 24 GyLarynx Dmean < 50 GyOral cavity Dmean < 30 GyBrain Brain stem Dmax < 55 GyCochlea Dmax < 54 GyOptic nerves Dmax < 55 GyOptic chiasm Dmax < 54 GyPelvis Bladder V60 Gy < 50%Dmax < 78 GyRectum V60 Gy < 50%Dmax < 74 GyFemoral head V50Gy < 10%The dose homogeneity inside the PTV were comparedusing the S-index associated with the differential dDVH
12:
(3)
where D(j) is the relative dose in voxel j of the lesion,Dmean is the average relative dose in the lesion and TVis the target volume in elementary voxels.
2.2.2 Statistical analysisFor each patient, to compare plan 2 with plan 1, thedifference in percentage was calculated as:ΔDose (%) = (DAAA– DMB) x 100 / DAAA (4)Positives values indicate that the calculated dose usingplan 2 with AAA was higher than the calculated usingplan 1 with MB (DAAA> DMB) and negative values meanthe opposite (DAAA< DMB).The Wilcoxon signed rank test was used to calculate thep-value. A bilateral statistical test was realized with anerror α = 5%, corresponding to a 95% confidenceinterval (95% CI). The dose difference is considered
significant if p < 0.05. Data are presented as average (µ)± standard deviation (SD). Spearman’s test was used tocalculate the correlation coefficient (r). A bootstrapsimulation method with 1000 random samplings wasused to calculate the 95% confidence interval, 95%CI. 13,
14
3. Results
3.1 Dose volume histograms (DVH)Tables 3 and 4 summarize the dosimetric and statisticalresults for PTVs and OARs. In Table 3, it can be seen thatAAA algorithms calculated a significantly lower dose forPTVs located in the lung, with p < 0.05. In Table 4, itappears clearly that, the dose calculated for OARs byAAA was higher than using the MB algorithm.Spearmen’s test showed a strong correlation with r > 0.9for all dosimetric parameters. Figure 1 shows cDVHcalculated using MB for plan 1 and AAA for plan 2.
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Tables 3: The dosimetric and statistical results for PTVs. The average (µ) presents the dose difference in % and SD presentsthe standard deviation.Cancer sites Dose µ ± SD 95% CI r-value p-valueLung Dmin -8.7 ±4.6 [ -10.1; -7.3] 0.94 0.01Dmean -1.8 ± 1.2 [-2.2 ; -1.5] 0.98 0.01D95% -6.8  ± 4.5 [-8.2 ; -5.5 ] 0.93 0.007Dmax 0.3 ± 2.6 [-0.5 ; 1.0] 0.97 0.7Breast Dmin 11.4± 17.6 [2.9 ; 20] 0.97 0.008Dmean 0.43 ± 0.67 [0.1 ; 0.8] 0.99 0.03D95% 5.2 ± 9.4 [0.4 ; 9.9 ] 0.99 0.01Dmax 6.7 ± 23.1 [-5.3 ; 18.0] 0.70 0.02Spine Dmin 9.2 ± 13.6 [3.7 ; 22.2] 0.91 0.03Dmean -1.7 ± 4.6 [-6.1 ; 2.6 ] 0.99 1.0D95% 2.8 ± 3.6 [-0.5 ; 6.2] 0.99 0.15Dmax 1.6 ± 4.9 [-3.1; 6.3 ] 0.99 0.83Head &neck Dmin -0.9 ± 1.6 [-1.4 ; 0.4] 0.99 0.12Dmean 0.66 ± 2.3 [ 0.2 ; 1.2 ] 0.98 0.44D95% -0.59 ± 0.88 [ -0.8 ; -0.4] 0.99 0.1Dmax 0.65 ± 0.57 [ 0.5 ; 0.8 ] 0.99 0.004Brain Dmin -0.12 ± 0.9 [ -0.4 ; 0.2] 0.99 1.0Dmean 0.0 4± 0.13 [0.01 ; 0.1] 0.99 0.67D95% -0.1± 0.6 [-0.3 ;0.1 ] 0.99 0.87Dmax 0.11 ± 0.3 [ 0.1; 0.2] 0.99 0.5Pelvis Dmin -0.02 ± 1.3 [-0.2 ; 0.2] 0.99 0.75Dmean 0.18 ± 0.62 [0.1 ; 0.3] 0.99 0.5D95% 0.12 ± 1.0 [-0.1 ; 0.3] 0.99 0.5Dmax 0.09 ± 0.4 [0.1 ; 0.2] 0.99 0.78
Figure 1: Cumulative dose volume histograms for lung calculated using the MB method with 1D heterogeneity correction forplan 1 and AAA for plan 2.
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Tables 4: The dosimetric and statistical results for OARs. The average (µ) presents the dose difference in % and SD presentsthe standard deviation.Cancer sites OARs Dose µ ± SD 95% CI r-value p-valueLung Lung (minus thePTV) V20 GyV30 GyDmean 8.1 ± 4.01.3 ± 6.11.9 ± [ 4.1 ; 12.1][-4.6 ; 7.3][-2.8 ; 6.7] 0.990.970.90 0.030.60.4Spinal cord Dmax 0.8 ± 1.0 [0.1 ; 1.8] 0.98 0.1Heart V40 Gy 1.4 ±3.2 [-1.6 ; 4.5] 0.99 0.3Breast Lung V20 GyV30 GyDmean 10.7 ± 10.312.4 ± 12.014.4 ± 8.0 [0.8 ; 20.8][1.1 ; 23.6][6.5 ; 22.3] 0.990.990.99 0.060.030.03Heart Dmax 19.2 ± 13.3 [6.9 ; 31.5] 0.99 0.03Spine Spinal cord Dmax 0.8 ±0.6 [0.2 ; 1.3] 0.99 0.03Kidney Dmean 2.0  ± 1.0 [0.1 ; 4.0] 0.99 0.8Head & neck Spinal cord Dmax 3.1 ± 1.5 [1.7 ; 4.5] 0.99 0.03Parotid Dmean 4.3 ± 4.4 [0.8; 6.0] 0.99 0.1Larynx Dmean 9.1 ± 15 [0.1 ; 4.7] 0.99 0.1Oral cavity Dmean -0.97 ± 7.6 [-8.4 ; 6.6] 0.99 0.1Brain Trunk Dmax 1.12 ± 1.1 [0.3 ; 2.6] 0.64 0.2Cochlea Dmax 3.7 ± 2.7 [1.8 ; 5.6] 0.98 0.01Optic nerves Dmax 2.4 ± 4.9 [1.8 ; 5.8] 0.99 0.3Optic chiasm Dmax 1.1 2.9 [-2.2 ; 4.3] 0.98 0.8
Pelvis Bladder V60 GyDmax 3.3 ±3.70.5 ± 0.5 [0.0 ; 6.9][-0.3 ; 2.6] 0.990.99 0.10.1Rectum V60 GyDmax 1.5± 2-0.2 ± 0.3 [0.7 ; 3.7][-0.5 ; 0.2] 0.990.99 0.10.1Femoral head V50 Gy 15.1 ± 38.3 [-7.9 ; 38.1 ] 0.92 0.2
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Figure 2: Boxplot for S-index obtained from MB method in plan 1 and AAA in plan 2 indicating the minimum (min), medianand maximum (max) values, as well as the 25th (Q1) and 75th (Q3) percentiles.
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Figure 3: Boxplot for quality indices obtained from MB method in plan 1 and AAA in plan 2 indicating the minimum (min),median and maximum (max) values, as well as the 25th (Q1) and 75th (Q3) percentiles.
4. DiscussionMany authors have evaluated the recent densitycorrection methods and algorithms in terms of theirabilities to accurately represent the dosedistribution.15-18 They observed a large impact on thedose calculation particularly for heterogeneous media.They suggested that these corrections and algorithmsshould be used for more accurate calculation duringclinical radiotherapy planning. Recently, numerousstudies, recommended using AAA or Acuros XB forcalculating the dose in heterogeneous media.7, 8, 20, 21, 22In our study, we tackled the problem of changing thecalculation algorithms from MB with 1D heterogeneitycorrection to AAA so as to offer the clinician treatmentplans that are much nearer to reality than the plansgenerated using the MB method. We raised the questionas to whether the clinician should adapt the doseprescription when moving from MB to AAA. We presenta detailed analysis of the differences between DVH and
quality indices for six typical treatment cases calculatedusing the two different algorithms. The MB method isnot very accurate as a correction method; it only takesinto account the density in 1D and it does not allow forchanges in lateral electron transport. Conversely, AAAmodels accommodate lateral electron transport. Weobserved that tissues with lower densities, such as lung,are subject to a significant difference between MB andAAA. The chest exhibits a highly heterogeneous anatomywith bone, lung and soft tissues. Usually treatmentconsists of both lateral and oblique beams, whichtraverse low-density lung tissue. Since AAA is moreaccurate in correcting for heterogeneity it showed adosimetric impact on the PTVs and OARs. Thus, thereare significant differences in the dose for PTVs and OARsfor lung, breast and spine. In clinical practice, the dosedistribution is not uniform over the PTVs due toheterogeneous tissue densities. Our comparison ofS-indexes showed that MB tends to give a better PTVcoverage with homogenous dose distribution.
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Nevertheless, the AAA method is closer to the realitybecause it takes into account the lateral electrontransport, as mentioned above. The observed differencein dose distribution is due to the effect of lateralelectrons and it is expected to be larger for tissue withlower density. This explains why AAA under estimatedthe dose for some areas of PTVs and hot spots in normaltissue outside the PTVs. However, the dose differencevaried from one cancer site to another and from patientto patient. This means that the geometric configuration,or the dose weight of beams, must be optimized to fulfilthe dose constraints for OARs.Whatever the differences are, Chaikh et al. showed thatthese differences could be quantified and presented bymeans of a color-code using the gamma index.23-24 Thegamma tool shows a visual representation of thedifference in dose distribution to the patient. Theyreported that the only realistic dose distribution is thatevaluated by the clinical results obtained to the benefitof the patient. Currently, in reality the representation ofthe dose distribution calculated by an algorithm hasclinical value when it is linked to the clinician’sexperience. These results should be discussed amongclinicians and medical physicists to decide whether amodification of the current prescription procedure andplan acceptability criteria should be considered.
5. ConclusionThis study should alert physicians to treatmentmodifications associated with a change from theModified Batho's method to AAA. The heterogeneitycorrection algorithms are not equal from the point ofview of their ability to calculate the dose, especially forlung, breast and spine cases. This is due to the fact thatAAA approximates lateral electron transport, whichshows a significant impact on dose distribution. Thephysicist should be careful when changing from olderalgorithms to newer algorithms, in order to maximallyprotect the healthy tissues and to continue to achieve anoptimal clinical outcome.
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